Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs)

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 3, 2009, Pages 266-271

  Yamagishi, Sho Ichi ^a   Matsui, Takanori ^a   Takenaka, Katsuhiko ^a   Nakamura, Kazuo ^a   Takeuchi, Masayoshi ^b   Inoue, Hiroyoshi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; Diabetes; Oxidative stress; PEDF; Platelets

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; PADGEM PROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; PYRIDOXAL 5 PHOSPHATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ADVANCED GLYCATION END PRODUCTS BOVINE SERUM ALBUMIN; ADVANCED GLYCATION END PRODUCTS-BOVINE SERUM ALBUMIN; BOVINE SERUM ALBUMIN; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; ANIMAL; DIABETIC ANGIOPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; RAT; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; EYE PROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; NADPH OXIDASE; NERVE GROWTH FACTORS; PLATELET ACTIVATION; PLATELET AGGREGATION; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SERPINS; SERUM ALBUMIN, BOVINE;

EID: 65649133985     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.906     Document Type: Article

References (33)

1. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-2299.
2. Bern MM. Platelet function in diabetes mellitus. Diabetes 1978; 27: 342-350.
3. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006; 3: 73-77.
4. Yamagishi SI, Edelstein D, Du XL, Brownlee M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 2001; 50: 1491-1494.
5. Waters DD. Early pharmacologic intervention and plaque stability in acute coronary syndromes. Am J Cardiol 2001; 88: 30K-36K.
6. Wiggins BS, Wittkowsky AK, Nappi JM. Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes. Pharmacotherapy 2001; 21: 320-337.
7. Tombran-Tink J, Chader CG, Johnson LV. PEDF: Pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53: 411-414.
8. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248.
9. Duh EJ, Yang HS, Suzuma I, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-829.
10. Spranger J, Osterhoff M, Reimann M, et al. Loss of antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2002; 50: 2641-2645.
11. Boehm BO, Lang G, Volpert O, et al. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003; 46: 394-400.
12. Yokoi M, Yamagishi S, Saito A, et al. Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2007; 91: 885-887.
13. Yamagishi S, Inagaki Y, Nakamura K, et al. Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004; 37: 497-506.
14. Yamagishi SI, Kikuchi S, Nakamura K, et al. Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1. Horm Metab Res 2006; 38: 546-548.
15. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003; 46: 284-287.
16. Yamagishi S, Nakamura K, Matsui T, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281: 20213-20220.
17. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Imaizumi T. Pigment epithelium-derived factor (PEDF) prevents diabetes-or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res 2006; 72: 86-90.
18. Takenaka K, Yamagishi S, Matsui T, et al. Pigment Epithelium-Derived Factor (PEDF) administration inhibits occlusive thrombus formation in rats: A possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis 2008; 197: 25-33.
19. Yamagishi S, Inagaki Y, Amano S, et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 2002; 296: 877-882.
20. Takeuchi M, Watai T, Sasaki N, et al. Neurotoxicity of acetaldehyde-derived advanced glycation end products for cultured cortical neurons. J Neuropathol Exp Neurol 2003; 62: 486-496.
21. Kuwano K, Ikeda H, Oda T, et al. Xanthine oxidase mediates cyclic flow variations in a canine model of coronary arterial thrombosis. Am J Physiol 1996; 270: H1993-H1999.
22. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
23. Ikeda H, Ueyama T, Murohara T, et al. Adhesive interaction between P-selectin and sialyl Lewis(x) plays an important role in recurrent coronary arterial thrombosis in dogs. Arterioscler Thromb Vasc Biol 1999; 19: 1083-1090.
24. Freedman JE, Sauter R, Battinelli EM, et al. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res 1999; 84: 1416-1421.
25. Peng L, Mundada L, Stomel JM, et al. Induction of heme oxygenase-1 expression inhibits platelet-dependent thrombosis. Antioxid Redox Signal 2004; 6: 729-735.
26. Csiszar A, Stef G, Pacher P, Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 557-558.
27. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897. 28. Jinnouchi Y, Yamagishi S, Matsui T, et al. Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice. Brain Res 2007; 1167: 92-100.
28. Nakamura K, Yamagishi S, Matsui T, et al. Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 2007; 170: 2159-2170.
29. Calzada C, Coulon L, Halimi D, et al. In vitro glycoxidized low-density lipoproteins and low-density lipoproteins isolated from type 2 diabetic patients activate platelets via p38 mitogen-activated protein kinase. J Clin Endocrinol Metab 2007; 92: 1961-1964.
30. Zoltowska M, Delvin E, Ziv E, et al. Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic psammomys obesus. Lipids 2004; 39: 81-85.
31. Hangaishi M, Taguchi J, Miyata T, et al. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Commun 1998; 248: 285-292.
32. Hasegawa Y, Suehiro A, Higasa S, Namba M, Kakishita E. Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. Thromb Res 2002; 107: 319-323.
33. Yatscoff RW, Mehta A, Gerrard JM, Thliveris J. Glycation of platelet protein in diabetes mellitus: lack of correlation with platelet function. Clin Biochem 1987; 20: 359-363.